Proximagen's objective is to become one of the world's leading companies developing therapeutics for patients suffering from diseases of the CNS, neuroinflammation/inflammation and oncology.
To achieve this, the company is establishing a pipeline of CNS, neuroinflammation, inflammation and oncology programmes spanning all phases of development.
We are taking a flexible approach to how far we develop our programmes before partnering or monetising them. In taking these decisions, we are mindful of a number of factors, including development risk, the progress of competitor programmes, our financial position and our belief that the retention of rights to certain territories is an important long-term value driver.
In order to achieve our objectives, we have developed the following five strategic priorities:
- Expand our pipeline through acquisition, in-licencing and partnering, thus building quality and critical mass in research and development
- Structure innovative deals and deferring consideration where possible
- Reduce duplicated costs through sector consolidation
- Build closer relationships with "Big Pharma"
With respect to our pipeline, either:
- Invest in programmes where the value inflection point is identifiable (such as establishing clinical proof of concept) and where such investment is justified by the potential returns, and then out-licensing the programme with the retention of rights in certain territories, or
- Out-license programmes prior to significant investment where it is commercially viable to do so.
|
